Sanford-Burnham Medical Research Institute;Pfizer Inc.
发明人:
申请号：
EP16818691.4
公开号：
EP3317297A4
申请日:
2016.06.29
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
